Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: Trends between 1996 and 2000 in 12 states

Journal of Acquired Immune Deficiency Syndromes

Volumn 40, Issue 5, 2005, Pages 609-616

  Gebo, Kelly A ^a   Fleishman, John A ^b   Moore, Richard D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

Author keywords

Highly active antiretroviral therapy; HIV; Hospitalization; Injection drug use; Liver disease

Indexed keywords

ADULT; AFRICAN AMERICAN; ARTICLE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISPANIC; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; ISCHEMIC HEART DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; METABOLIC DISORDER; MORTALITY; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HEART DISEASES; HIV INFECTIONS; HOSPITALIZATION; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

EID: 27944490365     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000171727.55553.78     Document Type: Article

References (47)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
2. Paul S, Gilbert HM, Ziecheck W, et al. The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS. 1999;13:415-418.
3. Mocroft A, Barry S, Sabin CA, et al. The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine. AIDS. 1999;13:1255-1261.
4. Baum SE, Morris JT, Gibbons RV, et al. Reduction in human immunodeficiency virus patient hospitalizations and nontraumatic mortality after adoption of highly active antiretroviral therapy. Mil Med. 1999;164:609-612.
5. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS. 1997;11(Suppl):F101-F105.
6. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med. 1997;336:1531-1532.
7. Beck EJ, Mandalia S, Williams I, et al. Decreased morbidity and use of hospital services in English HIV-infected individuals with increased uptake of anti-retroviral therapy 1996-1997. National Prospective Monitoring System Steering Group. AIDS. 1999;13:2157-2164.
8. Altes J, Guadarrama M, Force L, et al. The impact of highly active antiretroviral therapy on HIV-related hospitalizations in 17 county hospitals in Catalonia, Spain. Catalonian County Hospitals HIV Infection Study Group. AIDS. 1999;13:1418-1419.
9. Paul S, Gilbert HM, Lande L, et al. Impact of antiretroviral therapy on decreasing hospitalization rates of HIV-infected patients in 2001. AIDS Res Hum Retroviruses. 2002;18:501-506.
10. Spira R, Marimoutou C, Binquet C, et al. Rapid change in the use of antiretroviral agents and improvement in a population of HIV-infected patients: France, 1995-1997. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA). J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:358-364.
11. Gebo KA, Diener-West M, Moore RD. Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:143-152.
12. Gebo KA, Diener-West M, Moore RD. Hospitalization rates differ by hepatitis C status in an urban HIV cohort. J Acquir Immune Defic Syndr. 2003;34:165-173.
13. Martin-Carbonero L, Soriano V, Valencia E, et al. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses. 2001;17:1467-1471.
14. Gardner LI, Klein RS, Szczech LA, et al. Rates and risk factors for condition-specific hospitalizations in HIV-infected and uninfected women. J Acquir Immune Defic Syndr. 2003;34:320-330.
15. Soriano V, Martin-Carbonero L, Garcia-Samaniego J, et al. Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus. Clin Infect Dis. 2001;33:1793-1795.
16. Mocroft A, Monforte A, Kirk O, et al. Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. HIV Med. 2004;5:437-447.
17. Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS. 2001;15:231-239.
18. Behrens G, Schmidt H, Meyer D, et al. Vascular complications associated with use of HIV protease inhibitors. Lancet. 1998;351(9120):1958.
19. Gallet B, Pulik M, Genet P, et al. Vascular complications associated with use of HIV protease inhibitors. Lancet. 1998;351:1958-1959.
20. Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated with use of HIV protease inhibitors. Lancet. 1998;351(9120):1959.
21. Moore RD, Keruly JC, Lucas GM. Increasing incidence of cardiovascular disease in HIV-infected persons in care [abstract]. Presented at: 10th Conference on Retroviruses and Opportunistic Infections; 2003; Boston.
22. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993-2003.
23. Klein D, Hurley LB, Quesenberry CP, et al. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr. 2002;30:471-477.
24. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003;33:506-512.
25. Holmberg SD, Moorman AC, Greenberg AE, et al. The DAD Steering Committee. Trends in rates of myocardial infarction among patients with HIV. N Engl J Med. 2004;350:730-732.
26. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479-2486.
27. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet. 2002;360:1747-1748.
28. Bozzette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348:702-710.
29. Steiner C, Elixhauser A, Schnaier J. The healthcare cost and utilization project: an overview. Eff Clin Pract. 2002;5:143-151.
30. Fleishman JA, Hellinger FJ. Trends in HIV-related inpatient admissions from 1993 to 1997: a seven-state study. J Acquir Immune Defic Syndr. 2001;28:73-80.
31. Fleishman JA, Hellinger FH. Recent trends in HIV-related inpatient admissions 1996-2000: a 7-state study. J Acquir Immune Defic Syndr. 2003;34:102-110.
32. Fasciano NJ, Cherlow AL, Turner BJ, et al. Profile of Medicare beneficiaries with AIDS: application of an AIDS casefinding algorithm. Health Care Financ Rev. 1998;19:19-38.
33. Rosenblum L, Buehler JW, Morgan MW, et al. HIV infection in hospitalized patients and Medicaid enrollees: the accuracy of medical record coding. Am J Public Health. 1993;83:1457-1459.
34. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA. 1993;269:729-730.
35. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Supplemental Report. Atlanta: Centers for Disease Control and Prevention; 2001:7.
36. Long JS. Regression Models for Categorical and Limited Dependent Variables. Thousand Oaks, CA: Sage Publications; 1997.
37. Betz ME, Gebo KA, Barber E, et al. Patterns of diagnosis in hospital admissions in a multi-state cohort of HIV+ adults in 2001. Med Care. (in press).
38. Floris-Moore M, Lo Y, Klein RS, et al. Gender and hospitalization patterns among HIV-infected drug users before and after the availability of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;34:331-337.
39. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281:2305-2315.
40. Crystal S, Lo Sasso AT, Sambamoorthi U. Incidence and duration of hospitalizations among persons with AIDS: an event history approach. Health Serv Res. 1999;33:1611-1638.
41. Fleishman JA, Mor V, Laliberte LL. Longitudinal patterns of medical service use and costs among people with AIDS. Health Serv Res. 1995;30:403-424.
42. The HIV Research Network. Hospital and outpatient health services utilization among HIV-infected patients in care in 1999. J Acquir Immune Defic Syndr. 2002;30:21-26.
43. Gebo K, Fleishman J, Conviser R, et al. Racial and gender disparities in receipt of HAART persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr. 2005;38:96-103.
44. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2003. Atlanta: US Department of Health and Human Services; 2003.
45. Substance Abuse and Mental Health Services Administration. Results from the 2002 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NHSDA Series H-22, DHHS Publication No. SMA 03-3836). Rockville, MD: Department of Health and Human Services; 2003.
46. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12(Suppl):F51-F58.
47. Hommes MJ, Romijn JA, Endert E, et al. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism. 1991;40:651-656.